基线总代谢肿瘤体积可预测一线帕博利珠单抗治疗晚期NSCLC预后
本研究为单中心回顾性队列研究,纳入34例PD-L1≥50%的晚期NSCLC患者接受一线帕博利珠单抗治疗,另设40例EGFR突变接受EGFR-TKI治疗作为对照组。结果显示,帕博利珠单抗组中tMTV≥75 cm³患者的中位OS为4.7个月,显著短于tMTV<75 cm³患者的未达到(HR=5.37,95%CI 1.72-16.77,P=0.004),而对照组无此差异。提示tMTV≥75 cm³可作为PD-L1高表达晚期NSCLC一线帕博利珠单抗治疗预后不良的生物标志物。
要点
- tMTV≥75 cm³与一线帕博利珠单抗治疗晚期NSCLC患者更短OS相关(HR=5.37)。
- 该预后关联在EGFR-TKI对照组中未观察到(HR=1.43,P=0.411)。
- tMTV可能有助于筛选需在帕博利珠单抗基础上加化疗的患者。
核心结论
- 基线tMTV≥75 cm³提示PD-L1高表达晚期NSCLC一线帕博利珠单抗治疗预后不良。
研究设计与样本
- 单中心回顾性队列研究,纳入34例PD-L1≥50%的晚期NSCLC患者接受一线帕博利珠单抗治疗。
- 另设40例EGFR突变接受EGFR-TKI治疗的患者作为对照组。
- 仅纳入治疗开始前60天内[18F]FDG-PET/CT阳性者,tMTV以SUVmax阈值42%半自动勾画计算。
主要发现
- 帕博利珠单抗组中位随访20.3个月,tMTV≥75 cm³患者中位OS为4.7个月(95%CI 0.3-9.1),tMTV<75 cm³患者未达到(95%CI NR-NR)。
- tMTV≥75 cm³与更差OS显著相关(HR=5.37,95%CI 1.72-16.77,P=0.004)。
- 对照组中tMTV与OS无显著关联(HR=1.43,95%CI 0.61-3.34,P=0.411)。
关键数值与推荐
- tMTV以SUVmax阈值42%半自动勾画各病灶后求和获得。
- tMTV≥75 cm³为预后不良的临界值。
- PD-L1表达≥50%为帕博利珠单抗组入组条件。
临床怎么用
- 基线[18F]FDG-PET/CT计算的tMTV可辅助判断一线帕博利珠单抗治疗的预后风险。
- tMTV≥75 cm³患者可考虑在帕博利珠单抗基础上联合化疗。
局限性
- 单中心回顾性设计,样本量较小(帕博利珠单抗组34例)。
- tMTV临界值75 cm³需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have become the standard of care in the management of advanced non-small cell lung cancer (NSCLC). Nevertheless, only a small proportion of patients benefit from ICIs. The aim of the present study is to assess whether 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography ([18F]FDG-PET/CT)-derived parameters may be used as biomarkers in patients with advanced NSCLC receiving first-line pembrolizumab. MATERIALS AND METHODS: This is a monocentric retrospective cohort study including patients with advanced NSCLC (stage IV) and Programmed death-ligand 1 (PD-L1) expression ≥50% treated with pembrolizumab. A control group of patients treated with epidermal growth factor receptor (EGFR) inhibitors for EGFR-mutated NSCLC was also enrolled. Only patients with a positive [18F]18F-FDG PET/CT result within 60 days from treatment initiation were included.Total metabolic tumour volume (tMTV) was calculated for each lesion using a dedicated software (PET VCAR; GE Healthcare), which semiautomatically delineates the tumour's contours with a maximum standardised uptake value (SUVmax) threshold of 42% within the lesion. tMTV was obtained summing each lesion's MTV. Potential prognostic parameters for overall survival (OS) were analysed (tMTV, SUVmax, bone/liver metastasis, neutrophil:lymphocyte ratio ≥4, Eastern Cooperative Oncology Group performance status ≥2, lactate dehydrogenase above the upper limit of normal). RESULTS: Overall, 34 patients treated with first line-pembrolizumab and 40 patients treated with EGFR tyrosine kinase inhibitors were included. In the pembrolizumab group, the median follow-up was 20.3, while the median OS was 4.7 months (95% confidence interval [CI] = 0.3-9.1) for patients with tMTV ≥75 cm3 vs not reached (NR) for patients with tMTV <75 cm3 (95% CI = NR-NR; hazard ratio [HR] = 5.37; 95% CI = 1.72-16.77; p = 0.004). No difference was found in the control group (HR = 1.43; 95% CI = 0.61-3.34; p = 0.411). CONCLUSION: Our data suggest that tMTV ≥75cm3 can be used as a prognostic biomarker of poor outcomes in patients with PD-L1-high advanced NSCLC treated with first-line pembrolizumab. This information could be useful for the selection of patients who may require the addition of chemotherapy to pembrolizumab.
引用
- Dall'Olio FG, Calabrò D, Conci N, et al. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. Eur J Cancer. 2021. PMID: 33892411. doi:10.1016/j.ejca.2021.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。